Xenon Pharmaceuticals Inc. (XENE) Stock: Price, Forecast & Analyst Target
Xenon Pharmaceuticals Inc. (XENE) — MoonshotScore 56/100 (Fair band), calculated Nov 18, 2026. Price $37.56 (-0.50%), as of the Nov 19, 2026 trading session; market cap $3.69B.
Educational signal · not a buy or sell recommendation · How to read this
Xenon Pharmaceuticals Inc. · XENE · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Xenon Pharmaceuticals is a clinical-stage biotech company in Burnaby, Canada, developing ion channel modulators for neurological disorders including epilepsy. The central question is whether its lead potassium channel program reaches approval, with cash positioned to fund operations through the decade's end.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Xenon Pharmaceuticals (XENE)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but stalling growth and a full valuation. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.
- EPS beat 0 of the last 3 reports
- Altman Z 40.63 · Piotroski F 2
- ROE -50.3% · ROA -32.2% · current ratio 21.19
Holding back: soft growth
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 58 | Fair | |
| 58 | Fair | |
| 58 | Fair | |
| 58 | Fair | |
| 56 | Fair | |
| 56 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $37.56 | |
| Change on the day | -0.50% | |
| 52-week range | $33.38–$72.66 | |
| Market capitalisation | $3.69B | — |
| Shares traded on the day | 1.28M | |
| Beta (volatility vs the S&P 500) | 0.6 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Xenon Pharmaceuticals (XENE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Xenon Pharmaceuticals (XENE), and what does it report?
Short answer · as of
Xenon discovers and develops small-molecule drugs targeting ion channels in the central nervous system.
Research dated 2026-09-13.
The lead program is a potassium channel activator in late-stage trials for rare developmental epilepsy, advancing through clinical testing with support from strategic partnerships with larger pharmaceutical firms. Earlier-stage candidates address sodium channel inhibition and calcium channel modulation, expanding the therapeutic scope across multiple neurological conditions. Revenue remains minimal, and operations are entirely funded by cash reserves supplemented by occasional partnership revenues from licensing agreements with collaborators. This funding model depends on successful clinical progression and eventual regulatory approval of the lead candidate to reach commercialization.
What do the latest results show for Xenon Pharmaceuticals (XENE)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 3 reports.
Research dated 2026-09-13.
Recent results reflected ongoing research and development spending with minimal revenue recognition. Operating cash burn remained steady as the company advances clinical trials. Net loss widened from research expenses, but this is expected for a development-stage biotech without approved products.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
What are the financial strengths and risks for Xenon Pharmaceuticals (XENE)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Cash and investments position operations to continue into the coming years, with estimated runway extending beyond the current planning horizon into the decade's end. Debt is minimal and does not materially constrain operations. The principal risk is clinical trial failure of the lead potassium channel candidate, which would eliminate the company's primary commercial opportunity and force strategic reassessment or restructuring. Partnership agreements with larger companies provide secondary optionality and potential fallback pathways if the lead program encounters difficulties. The company's financial position offers sufficient time to pursue its development strategy, but the milestone dependency on clinical success remains absolute.
Data-derived red flags
- Negative return on equity (-50.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Xenon Pharmaceuticals (XENE)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.55M · EPS -4.57 · 10 analysts.
Research dated 2026-09-13.
The critical milestone is Phase III data readout for the lead potassium channel candidate in a major epilepsy indication, expected in the near term. Positive results would validate the ion channel approach and likely attract partnership or acquisition interest from larger pharmaceutical companies. Negative or ambiguous data would create existential pressure on the company's valuation and force strategic reassessment of the development portfolio. The Phase III program represents a make-or-break moment, as earlier-stage candidates, while scientifically interesting, lack the commercial immediacy required to support near-term cash needs. Management has guided that sufficient cash exists to fund operations into the decade's end, contingent on rational decision-making regarding the lead program's trajectory.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for XENE.
Checked against the records this page reads, on the dates shown above.
How does Xenon Pharmaceuticals compare with its peers?
Short answer
Xenon Pharmaceuticals's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Ion channel therapeutics for neurology remain scientifically validated and medically important. Xenon's portfolio spans multiple channels and indications, reducing dependence on any single drug. However, the company lacks development and commercialization scale versus larger biotech competitors with approved products and established patient networks.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.56 Nov 18, 2026 | $3.01B | 97 5-pillar Nov 18, 2026 | |
| $58.26 Nov 19, 2026 | $2.97B | 95 5-pillar Nov 18, 2026 | |
| $27.61 Nov 18, 2026 | $3.49B | 89 5-pillar Nov 18, 2026 | |
| $41.17 Nov 19, 2026 | $4.51B | 84 5-pillar Nov 18, 2026 | |
| $46.41 Nov 19, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| $17.83 Nov 18, 2026 | $3.08B | 68 5-pillar Nov 18, 2026 | |
| $14.22 Nov 19, 2026 | $4.99B | 67 5-pillar Nov 18, 2026 | |
| $26.20 Nov 19, 2026 | $3.37B | 66 5-pillar Nov 18, 2026 | |
| $14.86 Nov 19, 2026 | $3.03B | 63 5-pillar Nov 18, 2026 | |
| $21.89 Nov 18, 2026 | $3.71B | 62 5-pillar Nov 18, 2026 | |
| Xenon Pharmaceuticals (XENE) — this page | $37.56 | $3.69B | 56 |
| $56.31 Nov 19, 2026 | $2.76B | 45 5-pillar Nov 18, 2026 | |
| $81.90 Nov 19, 2026 | $7.32B | 26 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $46.00 – $90.00
- Consensus target
- $68.63
- Median target
- $67.00
- Revenue estimate
- $1.55M
- EPS estimate
- $-4.57
Consensus record · Captured .
Measured against a quoted price of $37.56 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 15, 2026
- Transactions
- 41
- Identified insiders
- 10
- Purchases
- 2
- Sales
- 5
- Other transactions
- 34
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held XENE in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0% | $0 | Sold out (was $14.40M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Xenon Pharmaceuticals (XENE)?
Common Questions About XENE (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
When will the company's key data readouts occur?
The lead potassium channel program in Phase III is expected to generate efficacy data in the near term, representing the primary commercial catalyst for company valuation and strategic options. Earlier-stage candidates targeting sodium inhibition and calcium modulation have scheduled milestone readouts along a staggered timeline, providing value optionality but representing pre-commercial stage development with extended timelines. The Phase III readout in the lead indication is the defining moment for the company's validation thesis and will likely determine the strategic pathway forward, whether toward partnership, acquisition, or continued independent development.
How does partnership with Neurocrine help?
Neurocrine is a neurology-focused biopharma partner with development and commercialization capabilities. The partnership validates the science but commits revenue upside to Neurocrine upon approval.
Could the company run out of cash?
Runway extends several years based on current burn rates and existing cash. However, if clinical trials stall or expansion is needed, external funding would be required, likely at unfavorable terms.
Why is insider selling happening?
Insider transactions are dominated by equity awards and vesting, not strategic selling, consistent with standard biotech practice. No material open-market share sales suggest management confidence in clinical progress.
What is the XENE stock price today?
The last price recorded for Xenon Pharmaceuticals Inc. (XENE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the XENE price target?
The analyst consensus price target for Xenon Pharmaceuticals Inc. (XENE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 17 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold XENE
Funds in our ETF coverage that list XENE among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 3.96% |